A citation-based method for searching scientific literature

Julie B Hjerpsted, Anne Flint, Ashley Brooks, Mads B Axelsen, Trine Kvist, John Blundell. Diabetes Obes Metab 2018
Times Cited: 49







List of co-cited articles
518 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Juan Pablo Frias, Michael A Nauck, Joanna Van, Mark E Kutner, Xuewei Cui, Charles Benson, Shweta Urva, Ruth E Gimeno, Zvonko Milicevic, Deborah Robins,[...]. Lancet 2018
237
8

Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta-analysis.
Feng Sun, Shanshan Wu, Jing Wang, Shuxia Guo, Sanbao Chai, Zhirong Yang, Lishi Li, Yuan Zhang, Linong Ji, Siyan Zhan. Clin Ther 2015
95
8


A randomized study investigating the effect of omeprazole on the pharmacokinetics of oral semaglutide.
Tine A Bækdal, Astrid Breitschaft, Andrea Navarria, Cilie W Hansen. Expert Opin Drug Metab Toxicol 2018
26
15

Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes.
Kirsten Dahl, Ashley Brooks, Firas Almazedi, Søren Tetens Hoff, Cristina Boschini, Tine A Baekdal. Diabetes Obes Metab 2021
5
80


Effect of exenatide on the steady-state pharmacokinetics of digoxin.
Prajakti A Kothare, Danny K W Soon, Helle Linnebjerg, Soomin Park, Clark Chan, Adeline Yeo, Maggie Lim, Kenneth F Mace, Stephen D Wise. J Clin Pharmacol 2005
53
6

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.
Silvio E Inzucchi, Richard M Bergenstal, John B Buse, Michaela Diamant, Ele Ferrannini, Michael Nauck, Anne L Peters, Apostolos Tsapas, Richard Wender, David R Matthews. Diabetes Care 2015
6

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
Michael Nauck, Anders Frid, Kjeld Hermansen, Nalini S Shah, Tsvetalina Tankova, Ismail H Mitha, Milan Zdravkovic, Maria Düring, David R Matthews. Diabetes Care 2009
787
6

Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1).
Carol Wysham, Thomas Blevins, Richard Arakaki, Gildred Colon, Pedro Garcia, Charles Atisso, Debra Kuhstoss, Mark Lakshmanan. Diabetes Care 2014
211
6


Liraglutide: short-lived effect on gastric emptying -- long lasting effects on body weight.
J Jelsing, N Vrang, G Hansen, K Raun, M Tang-Christensen, L Bjerre Knudsen. Diabetes Obes Metab 2012
111
6




Gut feelings about diabetes and GLP-1 receptor agonists: lessons to be learnt from studies in functional gastrointestinal disorders.
Christopher K Rayner, Karen L Jones, Tongzhi Wu, Michael Horowitz. Diabetes Obes Metab 2017
9
33

Regulation of glucose homeostasis by GLP-1.
Prashant Nadkarni, Oleg G Chepurny, George G Holz. Prog Mol Biol Transl Sci 2014
106
6


Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Anushka Patel, Stephen MacMahon, John Chalmers, Bruce Neal, Laurent Billot, Mark Woodward, Michel Marre, Mark Cooper, Paul Glasziou, Diederick Grobbee,[...]. N Engl J Med 2008
6


Effects of intensive glucose lowering in type 2 diabetes.
Hertzel C Gerstein, Michael E Miller, Robert P Byington, David C Goff, J Thomas Bigger, John B Buse, William C Cushman, Saul Genuth, Faramarz Ismail-Beigi, Richard H Grimm,[...]. N Engl J Med 2008
6


Relationships between oesophageal transit and solid and liquid gastric emptying in diabetes mellitus.
M Horowitz, A F Maddox, J M Wishart, P E Harding, B E Chatterton, D J Shearman. Eur J Nucl Med 1991
268
6

Effect of GLP-1 receptor agonist on gastrointestinal tract motility and residue rates as evaluated by capsule endoscopy.
Y Nakatani, M Maeda, M Matsumura, R Shimizu, N Banba, Y Aso, T Yasu, H Harasawa. Diabetes Metab 2017
19
15

Give the receptor a brake: slowing gastric emptying by GLP-1.
Jenny Tong, David D'Alessio. Diabetes 2014
27
11


Efficacy and Safety of Relamorelin in Diabetics With Symptoms of Gastroparesis: A Randomized, Placebo-Controlled Study.
Michael Camilleri, Richard W McCallum, Jan Tack, Sharon C Spence, Keith Gottesdiener, Fred T Fiedorek. Gastroenterology 2017
68
6

Ghrelin, CCK, GLP-1, and PYY(3-36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After RYGB.
Robert E Steinert, Christine Feinle-Bisset, Lori Asarian, Michael Horowitz, Christoph Beglinger, Nori Geary. Physiol Rev 2017
217
6

Pramlintide, an amylin analog, selectively delays gastric emptying: potential role of vagal inhibition.
M Samsom, L A Szarka, M Camilleri, A Vella, A R Zinsmeister, R A Rizza. Am J Physiol Gastrointest Liver Physiol 2000
98
6

Relamorelin Reduces Vomiting Frequency and Severity and Accelerates Gastric Emptying in Adults With Diabetic Gastroparesis.
Anthony Lembo, Michael Camilleri, Richard McCallum, Ramon Sastre, Cristian Breton, Sharon Spence, Jeffery White, Michelle Currie, Keith Gottesdiener, Elizabeth Stoner. Gastroenterology 2016
68
6

PLASMA INSULIN RESPONSE TO ORAL AND INTRAVENOUS GLUCOSE ADMINISTRATION.
H ELRICK, L STIMMLER, C J HLAD, Y ARAI. J Clin Endocrinol Metab 1964
667
6

Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
B Wang, J Zhong, H Lin, Z Zhao, Z Yan, H He, Y Ni, D Liu, Z Zhu. Diabetes Obes Metab 2013
126
6

Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
Michael A Nauck, Juris J Meier, Matthew A Cavender, Mirna Abd El Aziz, Daniel J Drucker. Circulation 2017
224
6

Liraglutide and obesity: a review of the data so far.
Ellen E Ladenheim. Drug Des Devel Ther 2015
44
6

Vasorelaxant effect of glucagon-like peptide-(7-36)amide and amylin on the pulmonary circulation of the rat.
H A Golpon, A Puechner, T Welte, P V Wichert, C O Feddersen. Regul Pept 2001
125
6

GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism.
Yazhou Li, TracyAnn Perry, Mark S Kindy, Brandon K Harvey, David Tweedie, Harold W Holloway, Kathleen Powers, Hui Shen, Josephine M Egan, Kumar Sambamurti,[...]. Proc Natl Acad Sci U S A 2009
375
6


Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways.
Kiwon Ban, M Hossein Noyan-Ashraf, Judith Hoefer, Steffen-Sebastian Bolz, Daniel J Drucker, Mansoor Husain. Circulation 2008
730
6

Pharmacology, physiology, and mechanisms of incretin hormone action.
Jonathan E Campbell, Daniel J Drucker. Cell Metab 2013
745
6

GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP.
Brian D Green, Katharine V Hand, Janette E Dougan, Bronagh M McDonnell, Roslyn S Cassidy, David J Grieve. Arch Biochem Biophys 2008
113
6


Lessons learned from the clinical development of oral peptides.
Morten Asser Karsdal, Bente Juul Riis, Nozer Mehta, William Stern, Ehud Arbit, Claus Christiansen, Kim Henriksen. Br J Clin Pharmacol 2015
36
8

Knockdown of GLP-1 Receptors in Vagal Afferents Affects Normal Food Intake and Glycemia.
Jean-Philippe Krieger, Myrtha Arnold, Klaus G Pettersen, Pius Lossel, Wolfgang Langhans, Shin J Lee. Diabetes 2016
125
6

Glucagon-like peptide 1 in health and disease.
Andreas Andersen, Asger Lund, Filip K Knop, Tina Vilsbøll. Nat Rev Endocrinol 2018
136
6

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
Matthew James Armstrong, Piers Gaunt, Guruprasad P Aithal, Darren Barton, Diana Hull, Richard Parker, Jonathan M Hazlehurst, Kathy Guo, George Abouda, Mark A Aldersley,[...]. Lancet 2016
749
6

Cardiovascular disease prevention strategies for type 2 diabetes mellitus.
Niki Katsiki, Francesco Purrello, Costas Tsioufis, Dimitri P Mikhailidis. Expert Opin Pharmacother 2017
30
10

Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials.
Matteo Monami, Besmir Nreu, Alessia Scatena, Barbara Cresci, Francesco Andreozzi, Giorgio Sesti, Edoardo Mannucci. Diabetes Obes Metab 2017
77
6


3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.
Carel W le Roux, Arne Astrup, Ken Fujioka, Frank Greenway, David C W Lau, Luc Van Gaal, Rafael Violante Ortiz, John P H Wilding, Trine V Skjøth, Linda Shapiro Manning,[...]. Lancet 2017
252
6



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.